Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
BNTX
BioNTech SE
CAPPED RATING
BioNTech SE (BNTX) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B); its weakest is Growth (D-).
Quantitative Factor Evaluation • Updated
Overall Rating
2.3
/ 5.0
C
Value
C+
Factor Score
2.6
/ 5.0
Growth
D-
Factor Score
1.1
/ 5.0
Profitability
B
Factor Score
3.5
/ 5.0
Momentum
C
Factor Score
2.4
/ 5.0
Revisions
C-
Factor Score
1.9
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
0.0
EV / EBITDA
32.7
Rev Growth YoY
-35.4%
Gross Margin
78.7%
Price Return 3M
-8.1%
Price Return 12M
-14.9%
Catalyst Signal
0.00
Market Cap
N/A
TTM Revenue
N/A
Price / Sales
8.2
ROE
-6.7%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-08-05 | C+ (2.6) | D- (1.1) | B (3.5) | C (2.4) | C- (1.9) | C (2.3) |
| 2026-08-04 | C+ (2.6) | D- (1.1) | B (3.5) | C (2.4) | C- (1.9) | C (2.3) |
| 2026-08-03 | C+ (2.6) | C- (2.0) | B (3.3) | C (2.4) | C- (2.0) | C (2.5) |
| 2026-08-02 | C+ (2.6) | C- (2.0) | B (3.3) | C (2.4) | C- (1.9) | C (2.4) |